News
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback